Feasibility and outcomes of fibreoptic endoscopic evaluation of swallowing following prophylactic swallowing rehabilitation in head and neck cancer
Roe, Justin W. G.
MetadataShow full item record
Patterson, J., Toft, K., McAuley, F., King, E., McLachlan, K., Roe, J.G.W. and Wells, M. (2019) 'Feasibility and outcomes of fibreoptic endoscopic evaluation of swallowing following prophylactic swallowing rehabilitation in head and neck cancer', Clinical Otolaryngology, 44(4), pp. 549-556.
Objectives: Investigate the feasibility and outcomes of fibreoptic endoscopic evalua‐tion of swallowing (FEES) following a programme of prophylactic swallowing exer‐cises in head and neck cancer (HNC) patients treated with radiotherapy.Design: Prospective, single cohort, feasibility study.Setting: Three head and neck cancer centres in Scotland.Participants: Pre‐radiotherapy HNC patients who consented to participate in a pro‐phylactic swallowing intervention.Outcome measures: Fibreoptic endoscopic evaluation of swallowing recruitment and retention rates, assessment acceptability and compliance, qualitative process evaluation.Results: Higher rates of recruitment and retention were achieved in centres where FEES equipment was available on‐site. Travel and anticipated discomfort were barri‐ers to recruitment. Data completion was high for all rating scales, with good reliabil‐ity. Following radiotherapy, swallowing safety significantly deteriorated for liquid boluses (P = 0.005‐0.03); pharyngeal residue increased for liquid and semi‐solid bo‐luses. Pharyngo‐laryngeal oedema was present pre‐treatment and significantly in‐creased post‐radiotherapy (P = 0.001). Patients generally reported positive experience of FEES for their own learning and establishing a baseline.Conclusions: Fibreoptic endoscopic evaluation of swallowing is an acceptable method of assessing patients for a prophylactic swallowing intervention and offers some ad‐ditional information missing from VF. Barriers have been identified and should be taken into account in order to maximise recruitment for future trials.